Microfluidic squeezing for intracellular antigen loading in polyclonal B-cells as cellular vaccines

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Szeto, Gregory Lee ^a,b   Van Egeren, Debra ^b   Worku, Hermoon ^a   Sharei, Armon ^a,b   Alejandro, Brian ^b   Park, Clara ^b   Frew, Kirubel ^a   Brefo, Mavis ^a   Mao, Shirley ^b   Heimann, Megan ^a   Langer, Robert ^a,b   Jensen, Klavs ^b   Irvine, Darrell J ^a,b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; VACCINE;

ANIMAL; B LYMPHOCYTE; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL PROLIFERATION; CYTOLOGY; DEVICES; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MECHANICAL STRESS; METABOLISM; MICROFLUIDIC ANALYSIS; MOUSE; PROCEDURES;

ANIMALS; ANTIGENS; ANTIGENS, CD40; ANTIGENS, CD86; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICROFLUIDIC ANALYTICAL TECHNIQUES; STRESS, MECHANICAL; VACCINES;

EID: 84930216531     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10276     Document Type: Article

References (59)

1. Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nature reviews. Cancer 12, 265-277, doi:10.1038/nrc3258 (2012).
2. Draube, A. et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PloS one 6, e18801, doi:10.1371/journal.pone.0018801 (2011).
3. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. The New England journal of medicine 363, 411-422, doi:10.1056/NEJMoa1001294 (2010).
4. Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature medicine 2, 52-58 (1996).
5. Burch, P. A. et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 6, 2175-2182 (2000).
6. Garcia, F. et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. The Journal of infectious diseases 203, 473-478, doi:10.1093/infdis/jiq077 (2011).
7. Lu, W., Arraes, L. C., Ferreira, W. T. & Andrieu, J. M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nature medicine 10, 1359-1365, doi:10.1038/nm1147 (2004).
8. Levy, Y. et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. European journal of immunology 44, 2802-2810, doi:10.1002/eji.201344433 (2014).
9. Anguille, S., Smits, E. L., Lion, E., van Tendeloo, V. F. & Berneman, Z. N. Clinical use of dendritic cells for cancer therapy. The Lancet. Oncology 15, e257-267, doi:10.1016/S1470-2045(13)70585-0 (2014).
10. Wennhold, K., Shimabukuro-Vornhagen, A., Theurich, S. & von Bergwelt-Baildon, M. CD40-activated B cells as antigenpresenting cells: the final sprint toward clinical application. Expert review of vaccines 12, 631-637, doi:10.1586/erv.13.39 (2013).
11. Lopez, J. A. et al. Single step enrichment of blood dendritic cells by positive immunoselection. Journal of immunological methods 274, 47-61 (2003).
12. Dudziak, D. et al. Differential antigen processing by dendritic cell subsets in vivo. Science 315, 107-111, doi:10.1126/science.1136080 (2007).
13. Ahmadi, T., Flies, A., Efebera, Y. & Sherr, D. H. CD40 Ligand-activated, antigen-specific B cells are comparable to mature dendritic cells in presenting protein antigens and major histocompatibility complex class I-and class II-binding peptides. Immunology 124, 129-140, doi:10.1111/j.1365-2567.2007.02749.x (2008).
14. Pozzi, L. A., Maciaszek, J. W. & Rock, K. L. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. Journal of immunology 175, 2071-2081 (2005).
15. Castiglioni, P., Gerloni, M. & Zanetti, M. Genetically programmed B lymphocytes are highly efficient in inducing anti-virus protective immunity mediated by central memory CD8 T cells. Vaccine 23, 699-708, doi:10.1016/j.vaccine.2004.06.028 (2004).
16. Kamphorst, A. O., Guermonprez, P., Dudziak, D. & Nussenzweig, M. C. Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes. Journal of immunology 185, 3426-3435, doi:10.4049/jimmunol.1001205 (2010).
17. Lanzavecchia, A. Antigen-specific interaction between T and B cells. Nature 314, 537-539 (1985).
18. Rock, K. L., Benacerraf, B. & Abbas, A. K. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. The Journal of experimental medicine 160, 1102-1113 (1984).
19. Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nature reviews. Immunology 12, 557-569, doi:10.1038/nri3254 (2012).
20. Heit, A. et al. CpG-DNA aided cross-priming by cross-presenting B cells. Journal of immunology 172, 1501-1507 (2004).
21. Tobian, A. A., Harding, C. V. & Canaday, D. H. Mycobacterium tuberculosis heat shock fusion protein enhances class I MHC cross-processing and-presentation by B lymphocytes. Journal of immunology 174, 5209-5214 (2005).
22. Hon, H., Oran, A., Brocker, T. & Jacob, J. B lymphocytes participate in cross-presentation of antigen following gene gun vaccination. Journal of immunology 174, 5233-5242 (2005).
23. Jiang, W., Lederman, M. M., Harding, C. V. & Sieg, S. F. Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells. Journal of immunology 186, 2080-2086, doi:10.4049/jimmunol.1001869 (2011).
24. Sharei, A. et al. A vector-free microfluidic platform for intracellular delivery. Proceedings of the National Academy of Sciences of the United States of America 110, 2082-2087, doi:10.1073/pnas.1218705110 (2013).
25. Nair-Gupta, P. et al. TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow crosspresentation. Cell 158, 506-521, doi:10.1016/j.cell.2014.04.054 (2014).
26. Ma, Y. et al. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. Journal of immunology 190, 5588-5599, doi:10.4049/jimmunol.1203216 (2013).
27. Robson, N. C., Donachie, A. M. & Mowat, A. M. Simultaneous presentation and cross-presentation of immune-stimulating complex-associated cognate antigen by antigen-specific B cells. European journal of immunology 38, 1238-1246, doi:10.1002/eji.200737758 (2008).
28. Deng, J. et al. Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response. Cancer research 74, 4133-4144, doi:10.1158/0008-5472.CAN-14-0708 (2014).
29. Fuchs, E. J. & Matzinger, P. B cells turn off virgin but not memory T cells. Science 258, 1156-1159 (1992).
30. Eynon, E. E. & Parker, D. C. Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens. The Journal of experimental medicine 175, 131-138 (1992).
31. Gerloni, M., Rizzi, M., Castiglioni, P. & Zanetti, M. T cell immunity using transgenic B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 101, 3892-3897, doi:10.1073/pnas.0400138101 (2004).
32. Filaci, G. et al. Spontaneous transgenesis of human B lymphocytes. Gene therapy 11, 42-51, doi:10.1038/sj.gt.3302132 (2004).
33. Coughlin, C. M., Vance, B. A., Grupp, S. A. & Vonderheide, R. H. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103, 2046-2054, doi:10.1182/blood-2003-07-2379 (2004).
34. Kondo, E. et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. Journal of immunology 169, 2164-2171 (2002).
35. Kim, Y. S. et al. CD40-targeted recombinant adenovirus significantly enhances the efficacy of antitumor vaccines based on dendritic cells and B cells. Human gene therapy 21, 1697-1706, doi:10.1089/hum.2009.202 (2010).
36. Sharei, A. et al. Plasma membrane recovery kinetics of a microfluidic intracellular delivery platform. Integrative biology: quantitative biosciences from nano to macro 6, 470-475, doi:10.1039/c3ib40215k (2014).
37. Cho, H. J. et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nature biotechnology 18, 509-514, doi:10.1038/75365 (2000).
38. Bourke, E., Bosisio, D., Golay, J., Polentarutti, N. & Mantovani, A. The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102, 956-963, doi:10.1182/blood-2002-11-3355 (2003).
39. Barrett, D. M. et al. Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16, 619-630, doi:10.1016/j.jcyt.2013.10.013 (2014).
40. Salih, H. R. et al. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies. Journal of immunology 167, 4059-4066 (2001).
41. Vanden Bush, T. J., Buchta, C. M., Claudio, J. & Bishop, G. A. Cutting Edge: Importance of IL-6 and cooperation between innate and adaptive immune receptors in cellular vaccination with B lymphocytes. Journal of immunology 183, 4833-4837, doi:10.4049/jimmunol.0900968 (2009).
42. Mumm, J. B. et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer cell 20, 781-796, doi:10.1016/j. ccr.2011.11.003 (2011).
43. Fujii, S., Shimizu, K., Shimizu, T. & Lotze, M. T. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 98, 2143-2151 (2001).
44. Chen, W. F. & Zlotnik, A. IL-10: a novel cytotoxic T cell differentiation factor. Journal of immunology 147, 528-534 (1991).
45. Geginat, J., Lanzavecchia, A. & Sallusto, F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101, 4260-4266, doi:10.1182/blood-2002-11-3577 (2003).
46. Foulds, K. E., Rotte, M. J. & Seder, R. A. IL-10 is required for optimal CD8 T cell memory following Listeria monocytogenes infection. Journal of immunology 177, 2565-2574 (2006).
47. Choi, S. O. et al. Intracellular protein delivery and gene transfection by electroporation using a microneedle electrode array. Small 8, 1081-1091, doi:10.1002/smll.201101747 (2012).
48. Xie, X. et al. Nanostraw-electroporation system for highly efficient intracellular delivery and transfection. ACS nano 7, 4351-4358, doi:10.1021/nn400874a (2013).
49. Jaspe, J. & Hagen, S. J. Do protein molecules unfold in a simple shear flow? Biophysical journal 91, 3415-3424, doi:10.1529/biophysj.106.089367 (2006).
50. Kandalaft, L. E. et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2, e22664, doi:10.4161/onci.22664 (2013).
51. Rapoport, A. P. et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117, 788-797, doi:10.1182/blood-2010-08-299396 (2011).
52. Mackensen, A. et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24, 5060-5069, doi:10.1200/JCO.2006.07.1100 (2006).
53. Chodon, T. et al. Adoptive transfer of MART-1T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clinical cancer research: an official journal of the American Association for Cancer Research 20, 2457-2465, doi:10.1158/1078-0432.CCR-13-3017 (2014).
54. Wherry, E. J. T cell exhaustion. Nature immunology 12, 492-499 (2011).
55. Deeths, M. J., Kedl, R. M. & Mescher, M. F. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. Journal of immunology 163, 102-110 (1999).
56. Redmond, W. L. & Sherman, L. A. Peripheral tolerance of CD8 T lymphocytes. Immunity 22, 275-284, doi:10.1016/j. immuni.2005.01.010 (2005).
57. Zhang, S., Zhang, H. & Zhao, J. The role of CD4 T cell help for CD8 CTL activation. Biochemical and biophysical research communications 384, 405-408, doi:10.1016/j.bbrc.2009.04.134 (2009).
58. Bevan, M. J. Helping the CD8(+) T-cell response. Nature reviews. Immunology 4, 595-602, doi:10.1038/nri1413 (2004).
59. Janssen, E. M. et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421, 852-856, doi:10.1038/nature01441 (2003).